Isis rises on trial data for babies with spinal muscular atrophy.

Most of the babies with spinal muscular atrophy who took the treatment, known as ISIS-SMN-RX, have lived longer without permanent ventilation and increased their ability to use their muscles, the Carlsbad, California-based company said in a statement Thursday. Most babies with spinal muscular atrophy type 1, the variety Isis aimed to treat, die within the first two years of life, according to the National Institutes of Health. [Extracted from the article]

Copyright of Bloomberg.com is the property of Bloomberg, L.P. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)